Acquired progressive lymphangioma: Case report with partial response to imiquimod 5% cream.

Autor: Salman A; Department of Dermatology, School of Medicine, Marmara University, Istanbul, Turkey., Sarac G; Department of Dermatology, School of Medicine, Marmara University, Istanbul, Turkey., Can Kuru B; Department of Dermatology, Goztepe Training and Research Hospital, Istanbul Medeniyet University, Istanbul, Turkey., Cinel L; Department of Pathology, School of Medicine, Marmara University, Istanbul, Turkey., Yucelten AD; Department of Dermatology, School of Medicine, Marmara University, Istanbul, Turkey., Ergun T; Department of Dermatology, School of Medicine, Marmara University, Istanbul, Turkey.
Jazyk: angličtina
Zdroj: Pediatric dermatology [Pediatr Dermatol] 2017 Nov; Vol. 34 (6), pp. e302-e304. Date of Electronic Publication: 2017 Sep 21.
DOI: 10.1111/pde.13283
Abstrakt: Acquired progressive lymphangioma (APL), or benign lymphangioendothelioma, is an unusual entity derived from vascular structures. Clinically and histopathologically it may resemble Kaposi's sarcoma and well-differentiated angiosarcoma, causing a diagnostic problem. We report an individual with APL initially diagnosed with Kaposi's sarcoma who underwent unnecessary laboratory testing. Imiquimod 5% cream stopped the progression of the lesion. Awareness of this rare entity may prevent patients from undergoing excessive testing. Imiquimod may be used as a safe, effective treatment option.
(© 2017 Wiley Periodicals, Inc.)
Databáze: MEDLINE
Externí odkaz: